drugset / Trial / NCT06253533
ICVAX as a HIV Therapeutic DNA Vaccine
Phase 1
Completed
45 enrolled
Immuno Cure Holding (HK) Limited
Shenzhen Immuno Cure Biomedical Company Limited · collabShenzhen Third People's Hospital · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
The clinical trial is a dose-escalation, randomized, double-blind, placebo-controlled phase I study at a single center to evaluate the safety, tolerability and immunogenicity of HIV Therapeutic DNA Vaccine, ICVAX, in clinically stable HIV patients under ART treatment.
Timeline
- Start
- 2023-02-14
- Primary completion
- 2024-09-30
- Completion
- 2025-08-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ICVAX | Unknown | 1 mg | Intramuscular |
| Subject | ICVAX | Unknown | 2 mg | Intramuscular |
| Subject | ICVAX | Unknown | 4 mg | Intramuscular |